Our Science
Cure Genetics has two unique technology platforms:
AIMS CAR-NKT, which has demonstrated its good safety profile in the first FIC pipeline targeting clear cell renal carcinoma in clinical studies by enhancing solid tumor infiltration, modulating the tumor microenvironment, and extending sustained expansion. It is also being expanded into other autologous/allogeneic/in vivo pipelines.
VELPTM platform, through the effective diversity of libraries, excellent library packaging compatibility, and a combination of DNA enrichment-RNA signal detection technologies, has completed licensing collaborations with MNCs and Biotech companies such as Boehringer Ingelheim (BI), and is actively advancing the transformation of products targeting the nervous system, heart, and kidneys.